Follistatin 344 is a research-only protein with no approved labeling and no established human dose. This page does not provide a protocol. Any amounts circulating informally are anecdotal and unverified, not medically established. Any use should start low and be supervised by a qualified clinician.
Overview
Follistatin 344 is a protein that works by binding and sequestering ligands such as myostatin and activin, rather than acting as a simple receptor agonist. Because there is no approved indication and its behavior depends heavily on isoform, binding, and delivery, there is no authoritative dose to cite.
Why there is no established dose
Unlike compounds with a commonly cited community range, follistatin does not have a stable, widely-agreed dosing pattern:
- Its effect is a binding relationship, not a simple mass-to-effect dose, so "how many milligrams" is not the meaningful question.
- Behavior differs sharply between protein injection and gene-therapy approaches, and between the FST-344 and FST-315 isoforms.
- Amounts vary between sources and are not standardized — there is no validated range to report.
How it is administered
Injectable follistatin ships as a lyophilized protein reconstituted with a sterile diluent, then given by injection.
- Any amount depends on reconstitution — diluent volume sets concentration, read as syringe units.
- Proteins are fragile and, as unregulated products, actual identity and purity are not verified.
Why oversight matters
Follistatin 344 has no regulator-approved framework, no defined contraindications, and no monitoring standard, and its mechanism intersects with growth-regulating pathways. Meaningful decisions belong within controlled research under expert supervision — not a fixed number from a vendor or forum.